Contrast-Induced Nephropathy after Endovascular Aneurysm Repair, Carotid and Peripheral Interventions

Author(s): Kosmas I. Paraskevas*, George Geroulakos, Demetrios V. Vlahakos

Journal Name: Current Vascular Pharmacology

Volume 18 , Issue 5 , 2020


Become EABM
Become Reviewer
Call for Editor

[1]
McCullough PA, Stacul F, Becker CR, et al. Contrast-induced nephropathy (CIN) Consensus working panel: executive summary. Rev Cardiovasc Med 2006; 7(4): 177-97.
[PMID: 17224862]
[2]
Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Contrast-induced nephropathy: an “all or none” phenomenon? Angiology 2015; 66(6): 508-13.
[http://dx.doi.org/10.1177/0003319714550309] [PMID: 25225196]
[3]
Sun G, Chen P, Wang K, et al. Contrast-induced nephropathy and long-term mortality after percutaneous coronary intervention in patients with acute myocardial infarction. Angiology 2019; 70(7): 621-6.
[http://dx.doi.org/10.1177/0003319718803677] [PMID: 30317864]
[4]
Yuan Y, Qiu H, Song L, et al. A New risk factor profile for contrast-induced acute kidney injury in patients who underwent an emergency percutaneous coronary intervention. Angiology 2018; 69(6): 523-31.
[http://dx.doi.org/10.1177/0003319717736157] [PMID: 29082747]
[5]
Lin KY, Shang XL, Guo YS, et al. Association of preprocedural hyperglycemia with contrast-induced acute kidney injury and poor outcomes after emergency percutaneous coronary intervention. Angiology 2018; 69(9): 770-8.
[http://dx.doi.org/10.1177/0003319718758140] [PMID: 29463106]
[6]
Azzalini L, Vilca LM, Lombardo F, et al. Incidence of contrast-induced acute kidney injury in a large cohort of all-comers undergoing percutaneous coronary intervention: Comparison of five contrast media. Int J Cardiol 2018; 273: 69-73.
[http://dx.doi.org/10.1016/j.ijcard.2018.08.097] [PMID: 30196995]
[7]
Radak D, Neskovic M, Otasevic P, Isenovic ER. Renal dysfunction following elective endovascular aortic aneurysm repair. Curr Vasc Pharmacol 2019; 17(2): 133-40.
[http://dx.doi.org/10.2174/1570161115666171116163203] [PMID: 29149818]
[8]
Ertas F, Avci E, Kiris T. The ratio of fibrinogen to albumin as a predictor of contrast-induced nephropathy after carotid angiography. Angiology 2019; 70(5): 458-64.
[http://dx.doi.org/10.1177/0003319718809200] [PMID: 30373374]
[9]
Paraskevas KI, Mikhailidis DP. Contrast-induced acute kidney injury in patients undergoing carotid artery stenting: an underestimated issue. Angiology 2017; 68(9): 752-6.
[http://dx.doi.org/10.1177/0003319716668934] [PMID: 27645233]
[10]
Al Adas Z, Lodewyk K, Robinson D, et al. Contrast-induced nephropathy after peripheral vascular intervention: Long-term renal outcome and risk factors for progressive renal dysfunction. J Vasc Surg 2019; 69(3): 913-20.
[http://dx.doi.org/10.1016/j.jvs.2018.06.196] [PMID: 30292616]
[11]
Cury MVM, Matielo MF, Brochado Neto FC, et al. The incidence, risk factors, and outcomes of contrast-induced nephropathy in patients with critical limb ischemia following lower limb angiography. Angiology 2018; 69(8): 700-8.
[http://dx.doi.org/10.1177/0003319718754984] [PMID: 29390867]
[12]
Crimi G, Leonardi S, Costa F, et al. Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY trial. Catheter Cardiovasc Interv 2015; 86(1): E19-27.
[http://dx.doi.org/10.1002/ccd.25822] [PMID: 25703119]
[13]
Messenger JC, Ho KK, Young CH, et al. The national cardiovascular data registry (NCDR) data quality brief: the NCDR data quality program in 2012. J Am Coll Cardiol 2012; 60(16): 1484-8.
[http://dx.doi.org/10.1016/j.jacc.2012.07.020] [PMID: 22999725]
[14]
Yuksel Y, Ayca B, Akin F. Predictors of mortality after percutaneous coronary intervention in patients with acute myocardial infarction. Angiology 2019; 70(7): 672.
[http://dx.doi.org/10.1177/0003319718816510] [PMID: 30518219]
[15]
Qin YH, Yan GL, Ma CL, Tang CC, Ma GS. Effects of hyperglycaemia and elevated glycosylated haemoglobin on contrast-induced nephropathy after coronary angiography. Exp Ther Med 2018; 16(1): 377-83.
[http://dx.doi.org/10.3892/etm.2018.6183] [PMID: 29896264]
[16]
Çinar T, Keskin M, Kaya A. Atrial fibrillation: a new risk factor for contrast-induced nephropathy. Angiology 2019; 70(5): 470.
[http://dx.doi.org/10.1177/0003319718802906] [PMID: 30261741]
[17]
Zhang E, Lu Y, Chen G, et al. Predictive value of hepatorenal status in contrast-induced nephropathy among patients receiving coronary angiography and/or intervention: a systematic review and meta-analysis. Angiology 2019; 70(7): 633-41.
[http://dx.doi.org/10.1177/0003319718816206] [PMID: 30525915]
[18]
Sun G, Chen JY, Liu Y. Contrast-induced nephropathy: further investigations about risk factors are required. Angiology 2019; 70(8): 784-5.
[http://dx.doi.org/10.1177/0003319719857376] [PMID: 31238705]
[19]
Ulus T. Protection against contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Angiology 2018; 69(10): 918.
[http://dx.doi.org/10.1177/0003319718790868] [PMID: 30058343]
[20]
Yayla Ç, Yayla KG, Ünal S, Açar B, Akboğa MK, Demirtaş K. N-acetylcysteine and contrast-induced nephropathy. Angiology 2018; 69(1): 85.
[http://dx.doi.org/10.1177/0003319717726473] [PMID: 28823176]
[21]
Fu N, Liang M, Yang S. High loading dose of atorvastatin for the prevention of serum creatinine and cystatin c-based contrast-induced nephropathy following percutaneous coronary intervention. Angiology 2018; 69(8): 692-9.
[http://dx.doi.org/10.1177/0003319717750903] [PMID: 29343076]
[22]
Liu LY, Liu Y, Wu MY, Sun YY, Ma FZ. Efficacy of atorvastatin on the prevention of contrast-induced acute kidney injury: a meta-analysis. Drug Des Devel Ther 2018; 12: 437-44.
[http://dx.doi.org/10.2147/DDDT.S149106] [PMID: 29535505]
[23]
Zhou X, Dai J, Xu X, et al. Comparative efficacy of statins for prevention of contrast-induced acute kidney injury in patients with chronic kidney disease: a network meta-analysis. Angiology 2019; 70(4): 305-16.
[http://dx.doi.org/10.1177/0003319718801246] [PMID: 30261736]
[24]
Yang SC, Fu NK, Zhang J, et al. Preventive effects of alprostadil against contrast-induced nephropathy inpatients with renal insufficiency undergoing percutaneous coronary intervention. Angiology 2018; 69(5): 393-9.
[http://dx.doi.org/10.1177/0003319717730942] [PMID: 29073785]
[25]
Xie J, Jiang M, Lin Y, Deng H, Li L. Effect of alprostadil on the prevention of contrast-induced nephropathy: A meta-analysis of 36 randomized controlled trials. Angiology 2019; 70(7): 594-612.
[http://dx.doi.org/10.1177/0003319719825597] [PMID: 30669852]
[26]
Zhan B, Huang X, Jiang L, Bao H, Cheng X. Effect of nicorandil administration on preventing contrast-induced nephropathy: A meta-analysis. Angiology 2018; 69(7): 568-73.
[http://dx.doi.org/10.1177/0003319717732237] [PMID: 28950711]
[27]
Paraskevas KI, Giannoukas AD, Kotsikoris I, Mikhailidis DP. Contrast-induced nephropathy and the vascular patient. Angiology 2010; 61(8): 721-3.
[http://dx.doi.org/10.1177/0003319710379110] [PMID: 20682609]
[28]
Katsiki N, Fonseca V, Mikhailidis DP. Contrast-induced acute kidney injury in diabetes mellitus: Clinical relevance and predisposing factors. Could statins be of benefit? J Diabetes Complications 2018; 32(11): 982-4.
[http://dx.doi.org/10.1016/j.jdiacomp.2018.08.008] [PMID: 30131213]


free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 5
Year: 2020
Page: [531 - 532]
Pages: 2
DOI: 10.2174/1570161117999190821145924

Article Metrics

PDF: 27
HTML: 2